Reviewed by the HyaluFlow Health Editorial Team | Published: July 8, 2026 | Last Updated: August 26, 2026

GLP-1 medicines such as semaglutide and liraglutide, plus tirzepatide, a dual GIP/GLP-1 medicine, can produce substantial weight loss. That weight loss can change facial volume and trigger temporary hair shedding, particularly when weight falls quickly.

Quick Answer: Facial volume loss and hair shedding can occur during substantial weight loss with these medicines. Evidence does not establish that GLP-1 drugs directly damage facial skin or hair follicles. Rapid weight reduction and the physiological stress of weight loss are plausible contributors to hair shedding, while facial changes are consistent with loss of subcutaneous fat.

Key Takeaways: “Ozempic face” is not a formal medical diagnosis. Facial changes are generally associated with loss of facial fat during weight reduction, while hair shedding can occur through mechanisms such as telogen effluvium. Evidence specifically linking these changes to the drugs themselves remains limited.

What Are GLP-1 and GIP/GLP-1 Medicines?

GLP-1 receptor agonists mimic an appetite- and glucose-regulating hormone. Semaglutide and liraglutide are GLP-1 receptor agonists, while tirzepatide activates both GIP and GLP-1 receptors.

The STEP 1 Trial published in the New England Journal of Medicine found substantially greater weight loss with once-weekly semaglutide 2.4 mg than placebo over 68 weeks. SURMOUNT-1, also published in the New England Journal of Medicine, similarly found substantial weight reduction with tirzepatide over 72 weeks.

Why Does “Ozempic Face” Happen?

“Ozempic face” is a popular term, not a formal diagnosis. It describes a thinner or more hollow facial appearance after significant weight loss.

Facial fat contributes to soft-tissue volume and facial shape. When subcutaneous fat decreases, cheeks and temples can look less full, while existing skin laxity may become more noticeable.

A 2026 clinical study examining facial changes associated with rapid weight loss largely related to GLP-1/GIP therapies is reported in Journal of Cosmetic Dermatology.

Why Can Hair Shed?

Hair shedding after rapid weight loss is consistent with telogen effluvium, a form of diffuse, non-scarring hair loss that can follow physiological stress or sudden weight loss. It often appears weeks or months after the trigger.

The review “Telogen Effluvium: A Review of the Science and Current Obstacles” in the Journal of Dermatological Science identifies sudden weight loss as a recognized trigger.

The evidence is more nuanced than saying GLP-1 drugs simply “do not cause hair loss.” A 2026 systematic review in PubMed: “GLP-1 therapies and hair loss” found reported associations with some GLP-1 therapies while noting that medication, weight loss, and other factors may all contribute.

The Zepbound prescribing information lists hair loss among common adverse reactions and states that hair loss in clinical trials was associated with weight reduction.

Who May Notice These Changes?

Changes may be more noticeable in people losing substantial weight, losing it quickly, consuming too few calories or protein, or already experiencing hair thinning or reduced skin elasticity. Age, genetics, nutritional status, and the amount of weight lost can also influence appearance.

How Can You Reduce the Impact?

Avoid crash dieting while taking a weight-loss medicine. Follow your clinician’s treatment plan and maintain adequate protein and overall nutrition.

Resistance training can help preserve lean mass during weight loss. Hydration and a consistent skincare routine can support skin comfort, but moisturizers cannot replace lost facial fat.

If hair shedding is significant, a clinician can evaluate nutrition, medications, thyroid problems, iron status, and other potential causes instead of assuming the medicine is solely responsible.

What the Science Says

The strongest evidence supports the weight-loss effects of these medicines. Evidence connecting facial changes specifically to GLP-1 treatment is thinner, while hair loss appears to have multiple possible explanations.

The evidence supports a cautious conclusion: these changes can occur during treatment, but it is too simplistic to describe them as direct toxicity to skin or hair.

Common Myths

Myth: “Ozempic directly melts facial tissue.” Reality: There is no good evidence that semaglutide selectively destroys facial tissue; loss of facial fat during weight reduction is a more plausible explanation.

Myth: “Hair loss means permanent follicle damage.” Reality: Telogen effluvium is typically non-scarring, although persistent or patterned hair loss needs evaluation.

Myth: “Stopping treatment automatically restores facial volume.” Reality: Facial volume does not necessarily return after stopping medication. Results depend on weight change, aging, skin elasticity, and individual anatomy.

Who Should Pay Attention?

Speak with a healthcare professional if hair loss is severe, patchy, persistent, or accompanied by symptoms such as marked fatigue. Sudden, asymmetric, or medically concerning facial changes also deserve assessment.

Evidence Strength Summary

  • Weight-loss efficacy: Strong.
  • Hair-loss association: Moderate but evolving.
  • Rapid-weight-loss/telogen-effluvium explanation: Moderate.
  • Direct facial damage from GLP-1 drugs: Insufficient evidence.

Bottom Line

GLP-1 and GIP/GLP-1 medicines can produce substantial weight loss, and visible facial or hair changes may accompany that process. The practical approach is to avoid crash dieting, maintain adequate nutrition, use resistance training, and discuss concerning changes with a healthcare professional rather than stopping treatment independently.